BNP Paribas Asset Management
RNAM

BNP Paribas Asset Management’s Avidity Biosciences RNAM Stock Holding History

BNP Paribas Asset Management’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-56,587
Closed -$4.08M – 2325
2025
Q4 		$4.08M Buy
+56,587
New +$3.66M ﹤0.01% 893
2025
Q3 		– Sell
-822
Closed -$23K – 2044
2025
Q2 		$23K Buy
+822
New +$24.5K ﹤0.01% 1456

Other funds holding RNAM

CC
Corsicana & Co Corsicana, Texas $206M AUM 26.42% 1-Year Est. Return

BNP Paribas Asset Management's RNAM Position: Q1 2026 in Review

BNP Paribas Asset Management sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 56,587 shares — an estimated $4.08M sold.

BNP Paribas Asset Management first reported a position in RNAM in Q2 2025 and held it in 2 quarters. The position peaked at $4.08M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

  • BNP Paribas Asset Management reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
  • BNP Paribas Asset Management sold 56,587 Avidity Biosciences shares in Q1 2026, an estimated $4.08M.
  • BNP Paribas Asset Management first reported a position in Avidity Biosciences in Q2 2025 and held it in 2 quarters.
  • BNP Paribas Asset Management's Avidity Biosciences position peaked at $4.08M in Q4 2025.
  • 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on BNP Paribas Asset Management's 13F filing for Q1 2026, filed 14 May 2026.